Trimel Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA regarding its CompleoTRT bioadhesive intranasal gel testosterone for the treatment of testosterone deficiency in men. According to the company, the intranasal gel is fully absorbed within half and hour and would avoid the potential transference problems presented by topic gel products.
Trimel President and CEO Tom Rossi commented, “This NDA filing is an important achievement for Trimel. If approved, CompleoTRT will provide men suffering from “Low T” with a novel treatment option. CompleoTRT is expected to offer hypogonadal patients the lowest efficacious delivered dose of testosterone in a convenient discreet device, without the risk for secondary transference.”
Read the Trimel press release.
